GDR — Genedrive Share Price
Last trade - 00:00- £8.90m
- £3.74m
- £0.50m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.66 | ||
| Price to Tang. Book | 1.66 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 17.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -99.12% | ||
| Return on Equity | -191.22% | ||
| Operating Margin | -1060.28% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 1.06 | 0.69 | 0.05 | 0.06 | 0.5 | n/a | n/a | -26.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- February 15th, 2007
- Public Since
- April 4th, 2007
- No. of Employees
- 43
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 624,895,408
- Address
- 48 Grafton Street, MANCHESTER, M13 9XX
- Web
- https://www.genedriveplc.com/
- Phone
- +44 1619890245
- Contact
- Paul Mcmanus
- Auditors
- RSM UK Audit LLP
Latest News for GDR
Upcoming Events for GDR
Full Year 2025 Genedrive PLC Earnings Release
Genedrive PLC Annual Shareholders Meeting
Similar to GDR
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Angle
London Stock Exchange
Aoti
London Stock Exchange
Aptamer
London Stock Exchange
FAQ
As of Today at 20:47 UTC, shares in Genedrive are trading at 1.43p. This share price information is delayed by 15 minutes.
Shares in Genedrive last closed at 1.43p and the price had moved by -16.18% over the past 365 days. In terms of relative price strength the Genedrive share price has underperformed the FTSE All Share Index by -21.66% over the past year.
The overall consensus recommendation for Genedrive is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreGenedrive does not currently pay a dividend.
Genedrive does not currently pay a dividend.
Genedrive does not currently pay a dividend.
To buy shares in Genedrive you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1.43p, shares in Genedrive had a market capitalisation of £8.90m.
Here are the trading details for Genedrive:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: GDR
Based on an overall assessment of its quality, value and momentum Genedrive is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Genedrive is 85.00p. That is 5864.91% above the last closing price of 1.43p.
Analysts covering Genedrive currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genedrive. Over the past six months, its share price has underperformed the FTSE All Share Index by -44.87%.
As of the last closing price of 1.43p, shares in Genedrive were trading -25.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genedrive PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 1.43p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Genedrive's management team is headed by:
- Ian Gilham - NEC
- David Budd - CEO
- Matthew Fowler - CFO
- Tom Lindsay - NED
- Christopher Yates - NED